Krystal Biotech, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 09, 2020 at 06:07 am EST
Share
Krystal Biotech, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 9.680 million compared to USD 5.342 million a year ago. Net loss was USD 9.610 million compared to USD 4.272 million a year ago. Basic loss per share was USD 0.49 compared to USD 0.25 a year ago. For the nine months, operating loss was USD 22.579 million compared to USD 15.927 million a year ago. Net loss was USD 21.784 million compared to USD 13.731 million a year ago. Basic loss per share was USD 1.18 compared to USD 0.89 a year ago.
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patientâs skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.
KRYSTAL BIOTECH, INC. 
